TY - JOUR
T1 - 6-Hydroxydopamine mediated cardiotoxicity in rabbits
AU - Lurie, Keith G
AU - Bristow, M. R.
AU - Minobe, W. A.
AU - Masek, M.
AU - Billingham, M. E.
PY - 1988/1/1
Y1 - 1988/1/1
N2 - Weekly injections of the catecholamine depleting agent 6-hydroxydopamine (6-OHDA) were used to denervate rabbit hearts chemically. Analyses of morphology and β-adrenergic receptor density were made at 1, 2, and 4 weeks. Changes resulting from subacute and chronic inflammatory processes were evident by light microscopy after 1 week. At that time, electron microscopy revealed marked increases in collagen, large myocytic vacuolizations in myocytes, widened gap junctions, and myofibrillar degeneration and dropout. Receptor density was marginally increased at 2 weeks but was decreased (p<.05) at 4 weeks (maximal [3H]dihydroalprenolol (DHA) binding in fmol/mg: 69.6 ± 5.4 in controls vs 49.2 ± 5.1 in 6-OHDA-treated animals). Basal, isoproterenol-stimulated and F--stimulated adenylate cyclase activities were decreased in the 6-OHDA-treated group at 4 weeks. We conclude that administration of 6-OHDA may cause severe myocardial damage, and that this process may involve loss of some functional components of the cell membrane.
AB - Weekly injections of the catecholamine depleting agent 6-hydroxydopamine (6-OHDA) were used to denervate rabbit hearts chemically. Analyses of morphology and β-adrenergic receptor density were made at 1, 2, and 4 weeks. Changes resulting from subacute and chronic inflammatory processes were evident by light microscopy after 1 week. At that time, electron microscopy revealed marked increases in collagen, large myocytic vacuolizations in myocytes, widened gap junctions, and myofibrillar degeneration and dropout. Receptor density was marginally increased at 2 weeks but was decreased (p<.05) at 4 weeks (maximal [3H]dihydroalprenolol (DHA) binding in fmol/mg: 69.6 ± 5.4 in controls vs 49.2 ± 5.1 in 6-OHDA-treated animals). Basal, isoproterenol-stimulated and F--stimulated adenylate cyclase activities were decreased in the 6-OHDA-treated group at 4 weeks. We conclude that administration of 6-OHDA may cause severe myocardial damage, and that this process may involve loss of some functional components of the cell membrane.
UR - http://www.scopus.com/inward/record.url?scp=0023782274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023782274&partnerID=8YFLogxK
M3 - Article
C2 - 3144992
AN - SCOPUS:0023782274
SN - 0887-8005
VL - 2
SP - 181
EP - 191
JO - American Journal of Cardiovascular Pathology
JF - American Journal of Cardiovascular Pathology
IS - 2
ER -